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Summary 
It has frequently been suggested that loss of Bz-microglobulin (B2m) in tumor cells may lead 
to malignant progression due to escape from immunological recognition. Here, we directly tested 
the role of fl2m expression in tumorigenicity.  A  ~2m loss mutant  (C4.4-25-),  selected from 
the murine lymphoma Eb4, showed a marked reduction in tumorigenicity as compared with 
Eb4 in normal  C57B1/6 (B6) mice. The reduced tumorigenicity  was directly related to ~2m 
expression.  Transfection  of an  intact  murine  ~2m  gene markedly  increased  the  tumorigenic 
potential.  The reduced tumorigenicity  of C4.4-25-  compared with fl2m transfected cells was 
observed also in athymic B6 nu/nu mice, but was abolished in B6 mice depleted of natural killer 
(NK)  1.1-positive cells.  These results  show that  restoration  of B2m  expression can promote 
tumorigenicity and demonstrate for the first time that  induction  of major histocompatibility 
complex class  I  expression by transfection  can lead to escape from NK cells  in vivo. 
M 
HC class I expression is often reduced or completely 
lost in tumors (1).  These molecules serve as restric- 
tion elements for CTL by presenting antigenic peptides de- 
rived from intracellularly degraded proteins (2). Thus, it has 
frequently been suggested that downregulated class I expres- 
sion may contribute to tumor progression by allowing es- 
cape  from  CTL-mediated  lysis.  Loss  of ~2-microglobulin 
(/~2m)  1 is one cause of MHC class I deficiency in tumors. In 
one study of 15 MHC class I-deficient colorectal adenocarci- 
nomas, loss of B2m was responsible for the absence of ma- 
ture HLA-A, -B, and -C heavy chains in all 15 cases (3). Ac- 
cordingly,  loss  of  fl2m  has  been  predicted  to  promote 
malignancy,  although  this  has  never been tested formally. 
To experimentally address the role of/~2m in malignancy 
is not trivial,  since target MHC class I molecules appear to 
have a protective effect against recognition by NK cells (4). 
This  concept  predicts  an  opposite  effect  of ~2m  loss  in 
tumorigenicity.  Loss of/~2m should reduce tumorigenicity 
due to elimination by NK cells while re-expression should 
restore it. 
We set out to test the role of ~/2m in tumorigenicity in 
a murine mutant-transfection  model. A ~2m-deficient mu- 
tant  of the  highly  tumorigenic  lymphoma  line  EL-4  was 
selected and subsequently transfected with a genomic clone 
1  Abbreviations used in this paper: /~gm, /~2-microglobulin; B6, C57B1/6; 
MNNG, N-methyl-N'-nitrosoguanidin. 
of the  murine  •2m b gene.  Transfections  resulted  in  class 
1-expressing cells which were used together with the 32m- 
deficient mutant to test tumorigenicity in syngeneic B6 and 
corresponding  athymic  B6  nu/nu  mice,  as  well  as  in  B6 
(C57B1/6) mice depleted of NK-l.l-positive cells. The out- 
come of the results was the opposite of that predicted from 
CTL studies.  Loss of ~2m expression was associated  with re- 
duced tumorigenicity, and restoration of ~2m expression led 
to an increased tumorigenic  potential. 
Materials and Methods 
Selection of Mutant Cell Lines and DNA-mediated  Gene Transfec- 
tion.  For  selection of the/~2m-deficient  mutant  C4.4-25-,  pa- 
rental  EL-4 (H-2  b) lymphoma  ceils were treated  twice with  10 
pg/ml  MNNG (N-methyl-N'-nitrosoguanidin).  Surviving  cells 
were subjected to complement treatment  (Low Tox Rabbit Com- 
plement; Cedarlane, Labs., Ltd., Hornby, Ontario,  Canada) after 
incubation with a mixture of anti-H-2K  b and D b mAbs B22.249, 
K10-56, and 28-8-6S; mAbs (5). After recovery of surviving cells, 
the complement  treatment  was repeated three times. Ceils were 
then subcloned four times by limiting dilution or single-ceU  sorting 
on a cell sorter (Coulter Corp., Hialeah, FL). Transfection was per- 
formed with a genomic fl2m  b clone combined on the same plasmid 
(constructed and kindly provided by Dr. P. Robinson, Medical Re- 
search Council, Harrow, UK) as the neo  R gene by electroporation, 
as described (5). Selection after transfection  was carried out in 
medium with 1.0 mg/ml or geniticin (G418, Gibco Laboratories, 
Uxbridge, UK). In vitro carried mutant  and  transfectant  lines 
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culture medium. 
Source of Mice, In  Vivo Tumorigenicity Tests, and NK Cell Deple- 
tion.  B6 and BALB/c mice were bred and maintained at the Depart- 
ment of Tumor Biology, Karolinska Institutet, or purchased from 
ALAB, Sollentuna, Sweden. Athymic B6 nu/nu  mice were pur- 
chased from G1. Bomholtgard, Ky, Denmark. Mice used in in vivo 
experiments were 5-8 wk old at the start of the experiments, usu- 
ally littermates, or otherwise age-matched within 2 wk.  Graded 
doses of in vivo-passaged  (6)  tumor cells were inoculated either 
subcutaneously (right flank) or intraperitoneally in a 0.1  ml vol 
of  PBS. Tumors always appeared at the site of  inoculation,  and tumor 
growth was followed at least once weekly by palpations and mea- 
surements at the tumor site. Mice were killed when the subcuta- 
neous tumors reached a size of >15 mm in diameter,  and no signs 
of rejection were observed. Mice without any signs of  tumor growth 
were kept under observation for at least 30 d after inoculation. Small 
groups of mice, never exceeding five mice per group, were tested 
in several independent tests throughout the study to minimize the 
risk of  random fluctuations in the quantity or quality of cells inoc- 
ulated.  For NK cell depletion in vivo, mice were given a single 
injection of 200 #1 ascites fluid prepared from mice inoculated in- 
traperitoneally with the anti-NKl.1 mAb 1 d before inoculation 
of tumor cells (7). 
Immunoprecipitation and SDS-PAGE.  Immunoprecipitation of 
MHC class I molecules from [3SS]methionine  metabolically labeled 
cells with  a rabbit  anti-mouse class I  antiserum  (K270,  kindly 
provided by Dr. L. Rask,  Biomedical Center, Uppsala,  Sweden) 
and subsequent analysis on a 13% SDS-PAGE was carried out as 
described (8). 
FACS  |  Analysis.  The cell surface expression of H-2D  b and K  b 
shown in Table 1 was measured on a FACS IV  |  (Becton Dickinson 
&  Co.,  Mountain  View,  CA)  with  the  anti-H-2D  b (28-14-8S) 
anti-H-2K  b (28-13-3S) mAbs  from the American Type Culture 
Collection (Rockville,  MD). 
In  Vitro Cell-mediated Cytotoxicity.  Anti-H-2b-specific  CTL 
effectors were generated in bulk MLCs by using splenocytes from 
BALB/c mice, preimmunized with B6 splenocytes,  as responders 
and irradiated splenocytes from B6 mice as stimulators. CTL were 
H-2  b specific since they also killed other H-2b-expressing  targets 
(RBL-5),  but  not  H-2d-expressing  targets  (P815)  (data  not 
shown).  A  standard 4-h SlCr-release assay was  used to measure 
cytotoxic activity. 
Results and Discussion 
FACS  |  analysis demonstrated that the EL-4-derived C4.4- 
25-  line was  class  I  deficient on  the cell surface (Table 1). 
This can be explained by lack of 32m expression.  No 32m 
could be coprecipitated with the class I H  chains as revealed 
by immunoprecipitation and subsequent SDS-PAGE analysis 
(Fig.  1).  Note the total absence of 32m and reduced molec- 
ular weight of the class I  H  chains isolated from the C4.4- 
25-  mutant (Fig. 1), the latter due to an arrest in transport 
through the Golgi complex where terminal glycosylation (in- 
creasing the mol wt) of class I H  chains normally would occur 
(9).  The mutant  was  completely resistant  to conventional 
anti-H-2  b allo-specific CTL lysis  (Table  1).  C4.4-25-  was 
transfected with a genomic clone of the murine fl2m  b gene. 
Two transfected clones, E50.15 + and E50.16 +, were isolated 
for  further  characterization.  These  clones  both  expressed 
Table  1.  Cell Su~ace MHC  Class I Expression and CTL 
Sensitivity of EL-4  Wild-Type,  Mutant,  and  Transfectant 
Cell Lines 
EL-4  C4.4-25-  E50.16+ 
Cell surface  class I 
expression*  H-2D  b 
H-2K  b 
CTL sensitivity*  E/T  40:1 
10:1 
2.5:1 
0.6:1 
0.16:1 
158  4  138 
166  2  141 
91  0  81 
83  0  67 
69  0  39 
44  0  20 
21  0  9 
* Mean linear fluorescence  value (background subtracted), one represen- 
tative analysis shown. 
* Percent specific lysis, one representative experiment shown. 
B2m which could be coprecipitated with the class I H  chains 
(Fig.  1;  E50.15 +,  data not  shown).  They expressed class  I 
molecules on the cell surface (Table 1; the E50.16 + line ex- 
pressed 62%  [SD  27%]  of D b and  65%  [SD  25%]  of K b 
compared with the EL-4 wild type line in an average of three 
independent experiments) and could be killed by allo anti-H- 
2b-specific CTL  (Table 1;  E50.15 +,  data  not  shown). 
Graded tumor doses of EL-4, C4.4-25-,  and E50.16 + cells 
were inoculated subcutaneously or intraperitoneally in normal 
Figure 1.  SDS-PAGE  analysis of class I 
mol~ales immanoprecipitated  from [3sS]me- 
thionine-labeled  EL-4  wild-type, mutant, and 
transfectant cells. Immunoprecipitates  made 
with a rabbit anti-mouse class I antiserum. 
HCs, heavy  chains. 
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/~2m-deficient  mutant  line  showed  a  markedly  reduced 
tumorigenic potential compared with the Eb4 wild-type line 
(Table  2).  In contrast,  the B2m-transfected C4.4-25-  line, 
E50.16 +, had regained tumorigenicity when compared with 
C4.4-25-.  When  tumors  appeared  after  inoculation  of 
C4.4-25-  mutant cells (Table 2), the latency period was usu- 
ally 2-3 wk longer than tumors derived from inoculates of 
E50.16 + cells. The effect of the B2m gene was not unique 
for the E50.16 + transfectant. The E50.15 + ~2m-transfected 
cell line also formed solid tumors after subcutaneous inocu- 
lation of 104 cells in four of five mice, and C4.4-25-  did not 
form any tumors in five mice inoculated in the same ex- 
periment. 
The differences in tumorigenicity between C4.4-25-  and 
E50.16 + transfectant lines remained in athymic nude (nu/nu) 
mice (Table 2).  However, the tumorigenicity of C4.4-25- 
compared with E50.16 + was restored in mice depleted of 
NKl.l-positive cells. In these mice both lines grew equally 
well (Table 2). This suggested that the C4.4-25-  line was 
eliminated by NK cells in vivo. Supporting this notion was 
an enhanced NK sensitivity in vitro of the C4.4-25-  line 
compared with Eb4 and E50.16 + (data not shown). Also 
compare the enhanced NK sensitivity in vitro of other ~2m- 
deficient EI.-4 lines (5). 
It should be noted that the tumorigenic potential of the 
E50.16 + transfectant never reached that of the EL-4 wild- 
type line although it was significantly increased compared 
with the C4.4-25-  line (Table 2). This result, at least partly, 
may be a reflection of the small (but consistent) reduction 
of class I levels on E50.16 + compared with the Eb4 wild- 
type line (Table 1). E50.16 § was also slightly less killed by 
CTL than EL,4 (Table  1). Note that the E50.16 + line was 
somewhat more tumorigenic in NKl.l-depleted mice than 
in normal untreated B6 mice (Table 2), which is consistent 
with a significantly reduced, but not totally abrogated NK- 
sensitive phenotype in vivo. 
To our knowledge, this is the first time that the ~2m gene 
directly has been demonstrated to protect a tumor from re- 
jection and thus promote tumorigenicity. The results sug- 
gest that the effect of 32m is due to altered interactions with 
the host, not due to the intrinsic growth properties. We con- 
dude that NK cells eliminate the C4.4-25-  cells because of 
the MHC class I-deficient phenotype and that this elimina- 
tion is abrogated by restoration of MHC class I expression 
at the cell surface. The results fit with in vitro results, demon- 
strating that NK cells can recognize and kill cells that fail 
to express MHC class I molecules, but not similar cells after 
restoration of MHC class I expression by class I/fl2m trans- 
fee*ion (reviewed in reference 4). They also support earlier 
studies in which MHC class I-deficient lymphoma cells were 
shown to be eliminated by NK cells in vivo (6, 10). The present 
results are in line with the observation that expression of re- 
cipient MHC class I molecules can protect tumor or bone 
marrow grafts from rapid dimination by NK cells. Expres- 
sion of a H-2D  d transgene protects B6 bone marrow, as well 
as lymphoma cells from rejection in H-2D a transgenic B6 
mice (11-13). Furthermore, 32m-deficient bone marrow cells 
are rejected by fl2m-expressing mice, and the marrow from 
flzm  +/-  littermates is accepted (14; (3hlrn et al., manu- 
script submitted for publication). 
The present results differ from several earlier studies of 
Table 2.  Tumor Growth after Subcutaneous or Intraperitoneal Inoculation of EL-4  Wild-Type, Mutant, and Transfectant Cell Lines 
Mice  Inoculation  No. of Cells 
(pretreatment)  site  inoculated 
Cell lines 
EL-4  C4.4-25-  E50.16 + 
C57B1/6  Subcutaneous  103  18/20"  0/15 
C57B1/6  Subcutaneous  104  20/20  1/20 
C57B1/6  Subcutaneous  103  20/20  2/20 
C57B1/6  Intraperitoneal  103  13/13  4/18 
C57B1/6  Intraperitoneal  104  14/14  6/19 
C57B1/6  Intraperitoneal  10  s  14/14  11/19 
C57B1/6  nu/nu  Subcutaneous  10  s  15/15  1/12 
C57B1/6  (NK 1.1)  Subcutaneous  103  ND  10/10 
C57B1/6  (NK 1.1)  Subcutaneous  104  ND  10/10 
C57B1/6  (NK  1.1)  Subcutaneous  10  s  ND  10/10 
1/20 
17/29' 
28/35* 
9/1311 
12/14S 
14/14rl 
13/14' 
8/11 
10/10 
10/10 
* Number of mice with tumor growth/total  number of mice inoculated; in five cases regression of established solid tumors 
ous inoculation of E50.16  + cells (one mouse inoculated with  103 cells, four mice inoculated with 103 cells). 
*  iv < 0.001 by X  2 analysis when compared with corresponding dose of C4.4-25-  cells. 
s p < 0.01. 
ir p  < 0.05. 
was seen after subcutane- 
845  Glas et al. MHC-dependent tumor rejection, many of which were per- 
formed with highly antigenic tumors, where transfection of 
class I molecules resulted in loss of tumorigenicity through 
escape  from T  cell  immunity (reviewed  in  reference  15). 
Tumorigenicity can also be altered by MHC class I transfec- 
tion through mechanisms independent of the host immune 
response (16, 17). Our results demonstrate a third possibility: 
reduced tumorigenicity associated with loss of class I expres- 
sion due to NK ceU-mediated rejection. 
This does not permit the generalized conclusion that ~/2m 
is a malignancy-promoting gene. The effects of variations in 
class I expression will depend on the dominating immunosur- 
veillance system in a certain situation, i.e., NK- (eliminating 
class I-deficient cells) or T cells (restricted to elimination of 
class I-positive cells if these harbor antigenic peptides bound 
to the class I antigen-binding groove) (discussed in reference 
4). However, the present study demonstrates that restoration 
of B2m/class I expression,  under certain circumstances,  can 
lead to increased  tumorigenicity. 
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